Neuronetics Inc- 詳細介紹、公司背景、業務範圍、財務數據以及市場表現

關於 Neuronetics Inc 公司

Neuronetics, Inc. a vertically integrated, commercial stage, medical technology and healthcare company. The Company’s NeuroStar Advanced Therapy (NeuroStar Therapy) is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions. In addition to selling the NeuroStar Advanced Therapy System (NeuroStar System) and associated treatment sessions to customers, it operates Greenbrook treatment centers across the United States, offering NeuroStar Therapy for the treatment of major depressive disorder (MDD) and other mental health disorders. Spravato is offered to treat adults with treatment-resistant depression and depressive symptoms in adults with MDD with suicidal thoughts or actions. MDD is a recurrent disease and follows a fluctuating course over an individual’s lifetime. The Company provides more than 7.1 million treatments to over 1,95,000 patients.

Neuronetics Inc簡介



公司代碼STIM

公司名稱Neuronetics Inc

上市日期Jun 28, 2018

CEOMr. Keith J. Sullivan

員工數量716

證券類型Ordinary Share

年結日Jun 28

公司地址3222 Phoenixville Pike

城市MALVERN

上市交易所NASDAQ OMX - NASDAQ BASIC

國家United States of America

郵編19355

電話18776007555

網址https://neurostar.com/neuronetics/

公司代碼STIM

上市日期Jun 28, 2018

CEOMr. Keith J. Sullivan

Neuronetics Inc公司高管



名稱

名稱/職務

職務

持股

持股變動

Mr. Sasha Cucuz

Director

2.03M

--

Mr. Steven Pfanstiel

Chief Financial Officer, Executive Vice President, Treasurer

828.78K

+1.03%

Mr. Robert A. (Rob) Cascella

Independent Non-Executive Chairman of the Board

588.77K

--

Mr. Glenn P. Muir

Independent Director

310.45K

-8.05%

Ms. Sheryl L. Conley

Independent Director

160.35K

-15.59%

Ms. Megan Rosengarten

Independent Director

140.89K

--

Mr. Mark Klausner

Managing Partner

--

Mr. W. Andrew Macan

Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary

--

Dr. Avinash N. Amin, M.D.

Director

--

名稱

名稱/職務

職務

持股

持股變動

Mr. Sasha Cucuz

Director

2.03M

--

Mr. Steven Pfanstiel

Chief Financial Officer, Executive Vice President, Treasurer

828.78K

+1.03%

Mr. Robert A. (Rob) Cascella

Independent Non-Executive Chairman of the Board

588.77K

--

Mr. Glenn P. Muir

Independent Director

310.45K

-8.05%

Ms. Sheryl L. Conley

Independent Director

160.35K

-15.59%

Ms. Megan Rosengarten

Independent Director

140.89K

--

收入明細

單位: USD更新時間: 4月6日週一

FY2025

FY2025Q4

FY2025Q3

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

FY2019

業務USD

名稱

營收

佔比

Clinic revenue

86.98M

58.31%

Treatment sessions

44.41M

29.77%

NeuroStar Advanced Therapy System

15.54M

10.42%

Other

2.24M

1.50%

地區USD

名稱

營收

佔比

United States

146.05M

97.92%

International

3.11M

2.08%

業務

地區

業務USD

名稱

營收

佔比

Clinic revenue

86.98M

58.31%

Treatment sessions

44.41M

29.77%

NeuroStar Advanced Therapy System

15.54M

10.42%

Other

2.24M

1.50%

股東統計

更新時間: 5月14日週四

持股股東

股東類型

持股股東

佔比

Madryn Asset Management, LP

29.80%

Chernett (Jorey)

14.34%

Parian Ultreia LP

6.96%

UBS Financial Services, Inc.

4.13%

Balyasny Asset Management LP

3.67%

其他

41.11%

持股股東

佔比

Madryn Asset Management, LP

29.80%

Chernett (Jorey)

14.34%

Parian Ultreia LP

6.96%

UBS Financial Services, Inc.

4.13%

Balyasny Asset Management LP

3.67%

其他

41.11%

股東類型

持股股東

佔比

Private Equity

29.80%

Individual Investor

24.40%

Investment Advisor

17.45%

Hedge Fund

10.25%

Corporation

6.96%

Investment Advisor/Hedge Fund

4.75%

Research Firm

2.27%

Venture Capital

0.45%

Bank and Trust

0.13%

其他

3.54%

機構持股



更新時間: 4月1日週三

報告期間

機構數

持股數

持股佔比

持股變動

2026Q1

236

47.87M

68.80%

-7.19M

2025Q4

216

42.35M

61.84%

-15.92M

2025Q3

198

39.45M

57.60%

-13.65M

2025Q2

187

47.56M

71.93%

-4.03M

2025Q1

191

47.19M

71.70%

-4.84M

2024Q4

155

36.70M

70.38%

+11.74M

2024Q3

153

14.58M

47.42%

-9.85M

2024Q2

159

20.22M

66.61%

-5.87M

2024Q1

183

20.38M

68.24%

-3.49M

2023Q4

191

18.37M

63.28%

-7.87M

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

Madryn Asset Management, LP

20.74M

29.93%

+2.26M

+12.24%

Mar 02, 2026

Chernett (Jorey)

9.78M

14.12%

+2.95M

+43.24%

Mar 31, 2026

Parian Ultreia LP

4.84M

6.99%

+4.84M

--

Mar 17, 2026

UBS Financial Services, Inc.

2.61M

3.76%

+442.22K

+20.43%

Dec 31, 2025

Balyasny Asset Management LP

2.55M

3.68%

+730.75K

+40.12%

Dec 31, 2025

BlackRock Institutional Trust Company, N.A.

2.17M

3.13%

+43.34K

+2.04%

Dec 31, 2025

Cucuz (Sasha)

2.03M

2.93%

+6.41K

+0.32%

Oct 20, 2025

Lane Generational, LLC

1.71M

2.46%

+1.71M

--

Dec 31, 2025

Sullivan (Keith J)

1.59M

2.3%

+66.21K

+4.34%

Mar 19, 2026

持股ETF



更新時間: 12月6日週六

機構名稱

佔比

AdvisorShares Psychedelics ETF

3.31%

Invesco NASDAQ Future Gen 200 ETF

0.43%

iShares Neuroscience and Healthcare ETF

0.1%

Vanguard US Momentum Factor ETF

0.04%

iShares Micro-Cap ETF

0.02%

iShares Russell 2000 Growth ETF

0.01%

Goldman Sachs ActiveBeta US Small Cap Equity ETF

0.01%

Avantis US Small Cap Equity ETF

0%

ProShares Hedge Replication ETF

0%

Proshares Ultra Russell 2000

0%

AdvisorShares Psychedelics ETF

佔比3.31%

Invesco NASDAQ Future Gen 200 ETF

佔比0.43%

iShares Neuroscience and Healthcare ETF

佔比0.1%

Vanguard US Momentum Factor ETF

佔比0.04%

iShares Micro-Cap ETF

佔比0.02%

iShares Russell 2000 Growth ETF

佔比0.01%

Goldman Sachs ActiveBeta US Small Cap Equity ETF

佔比0.01%

Avantis US Small Cap Equity ETF

佔比0%

ProShares Hedge Replication ETF

佔比0%

Proshares Ultra Russell 2000

佔比0%

分紅派息



近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股



公告日期

除權除息日

類型

比率

暫無數據

公告日期

除權除息日

類型

比率

暫無數據